The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing

Bottom line: The evidence suggesting psilocybin microdosing may improve well-being, mood, and creativity is limited and was associated with methodological flaws and self-reported outcomes.

At 2 a.m. during a Zoom call, someone swishes a spoonful of liquid in their mouth. It’s not a pill. It’s a microdose. They believe it’s sharpening their focus, brightening their mood, or even boosting their creativity. They’re not alone. Tens of thousands of people around the world say they’re microdosing—taking tiny amounts of psilocybin, the psychoactive compound in magic mushrooms or truffles. But what if the real magic isn’t the mushroom itself? What if it’s the belief that it might work?

A new systematic review asks these questions. It’s not about whether microdosing works. It’s about how much we really know. And the answer is complicated.

The promise and the puzzle

Microdosing has become a cultural phenomenon. People in Silicon Valley, wellness retreats, and everywhere in between are trying it. The idea is that a tiny, sub-perceptual dose of psychedelics can enhance productivity, creativity, and emotional well-being without the full-blown trip. But the science behind it is still in its infancy.

The new review, published in Frontiers in Psychiatry, pulls together 11 studies involving over 3,200 adults. It’s the most comprehensive look at microdosing to date—and it paints a picture that’s both promising and problematic.

The studies report that microdosing psilocybin mushrooms or truffles may improve well-being, mental health, cognition, physical health, creativity, relationships, pain, curiosity, and even substance dependence. But the evidence is far from solid. Most of the research is qualitative, meaning it relies on self-reported outcomes rather than objective measures. And many of the studies have methodological flaws—small sample sizes, lack of control groups, or unclear dosing protocols.

What’s more, the majority of people microdosing do so for non-medical reasons. Only 14% of participants cited a medical diagnosis, mostly related to mental health. This suggests that the appeal of microdosing is more about the promise of self-improvement than a cure for a specific condition.

The dose and the dose response

One of the biggest challenges in microdosing research is the lack of standardization. The review found extreme heterogeneity in dosing protocols and preparations. Some studies used dried mushrooms, others used truffles or extracts. The amount used varied widely, with no clear consensus on what constitutes a “microdose.” This makes it hard to compare results across studies, let alone draw definitive conclusions.

The review also highlights a critical gap in the literature: the absence of long-term data. Most studies are short-term, lasting a few weeks or months, and they don’t track participants over years. This means we don’t know whether the benefits of microdosing are sustained or if there are any long-term risks. For instance, what happens to people who microdose for years? Are there cumulative effects, or are the benefits just a fleeting glow?

Another surprising finding is that the majority of studies didn’t report adverse events at all. For those that did, the side effects were mostly mild—nausea, fatigue, or anxiety—but they were rarely detailed. This raises a question: are we missing something? Are there more serious risks that haven’t been adequately studied?

The placebo question

The review doesn’t just highlight the gaps—it also raises a bigger question: is microdosing even real? Some researchers argue that the reported benefits may be largely due to the placebo effect. After all, people who believe in the power of microdosing are more likely to report positive outcomes. This is the crux of the debate that has been playing out in academic circles for years.

A recent paper in Journal of Psychopharmacology argues that the evidence for microdosing as a placebo is premature. The authors point out that most studies have small sample sizes, and that the doses used are often too low to produce any measurable effect. They also note that some studies have shown dose-dependent effects, suggesting that the benefits are real and not just the result of expectation.

But even if the placebo effect plays a role, that doesn’t mean microdosing is all in our heads. The review suggests that there may be real physiological changes at play. For instance, some studies have found that microdosing may affect brain activity, mood, and even cognitive function. These findings, while preliminary, are enough to warrant further investigation.

The road ahead

What’s clear from the review is that the science of microdosing is still in its early stages. The authors call for more rigorous, well-powered randomized controlled trials with standardized dosing protocols. They also emphasize the need for mandatory reporting of adverse events and funding sources to build a more transparent and reliable body of evidence.

But even with these calls to action, the path forward is not straightforward. Microdosing is a complex phenomenon that involves not just the chemistry of psilocybin, but also the psychology of belief, the culture of wellness, and the individual’s unique response to substances. It’s a puzzle that doesn’t have a single answer.

Frequently asked questions

Q: Can microdosing really improve my mood or creativity?
A: Some studies suggest that it may, but the evidence is not strong enough to draw definitive conclusions. Most of the research is based on self-reported outcomes, and there are no large-scale, well-controlled trials to confirm these effects.

Q: Is microdosing safe?
A: Most studies report that the side effects are mild, but the long-term safety of microdosing is not well understood. There is no evidence of serious harm, but more research is needed to determine if there are any cumulative risks.

Q: Why do people microdose?
A: The majority of people microdose for non-medical reasons, such as improving focus, creativity, or mood. Only a small percentage use it for medical conditions, primarily mental health issues.

Q: Is microdosing a placebo?
A: Some researchers argue that the placebo effect may play a role, but the review suggests that there may be real physiological changes at play. The answer is not yet clear.

Q: What’s next for microdosing research?
A: The review calls for more rigorous, well-powered randomized controlled trials with standardized dosing protocols. Researchers also emphasize the need for mandatory reporting of adverse events and funding sources to build a more transparent and reliable body of evidence.

Sources

• ¶The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing
• ¶Is Microdosing a Placebo?
• ¶Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.